PHARMACEUTICAL FORMULATION OF RISEDRONATE

摘要

The present invention relates to an oral pharmaceutical dosage formulation comprising [1-hydroxy-2-(3-piridinyl)ethylidene]bisphosphonic acid, herein after referred to as risedronate for treating of osteoporosis. The present invention also relates to a manufacturing process for the preparation of risedronate tablets. This formulation also discloses a use of risedronate having a specifically selected particle size range and use of the excipients that ensure adequate flowability of a dry blend as well as required content uniformity and drug release rate of the final product.